Old Web
English
Sign In
Acemap
>
authorDetail
>
L. Gleich
L. Gleich
Cancer research
Philadelphia Chromosome Positive
Imatinib
Medicine
Pathology
3
Papers
74
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors.
2008
Journal of Clinical Oncology
Javier Pinilla-Ibarz
H. Kantarjian
J. E. Cortes
P. le Coutre
Arnon Nagler
Andreas Hochhaus
Daniel N. Jones
Shinya Kimura
J. Giampalmi
L. Gleich
O. Ottmann
Show All
Source
Cite
Save
Citations (25)
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
2007
Journal of Clinical Oncology
Adam Craig
H. Kantarjian
J. E. Cortes
Dan Jones
Andreas Hochhaus
Susan O'Brien
Mary Beth Rios
C. Zander
L. Gleich
E. P. Carroll
Oliver G. Ottmann
Show All
Source
Cite
Save
Citations (21)
Overexpression and amplification of glutathione S-transferase pi gene in head and neck squamous cell carcinomas.
1997
Clinical Cancer Research
Xin Wang
Z. P. Pavelic
Y. Li
L. Gleich
Peter S. Gartside
L Pavelic
Jack L. Gluckman
Peter J. Stambrook
Show All
Source
Cite
Save
Citations (28)
1